Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and
direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in …

Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many
years for patients with AF and other thrombotic conditions. The introduction of direct oral …

Importance Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin
for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

SNIIRAM/SNDS, the French administrative health care database, covers around 99% of the
population. Its main limitation is the absence of clinical information and biological results …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Abstract Background and Aim Anticoagulants play an important role in the management of
Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting …

Objective: To conduct a systematic review of real-world (RWD) studies comparing the risk of
major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …